CM Management’s Edesa Biotech EDSA Stock Holding History

CM Management’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-110,000	Closed	-$185K	–	58
2024 Q4	$185K	Hold	110,000	–	–	0.17%	55
2024 Q3	$490K	Buy	110,000 +20,000	+22%	+$90.9K	0.39%	55
2024 Q2	$385K	Buy	90,000 +28,000	+45%	+$125K	0.35%	56
2024 Q1	$260K	Hold	62,000	–	–	0.22%	66
2023 Q4	$283K	Buy	62,000 +2,343	+4%	+$8.88K	0.23%	68
2023 Q3	$264K	Buy	59,657 +6,086	+11%	+$35.9K	0.28%	57
2023 Q2	$304K	Buy	53,571 +7,142	+15%	+$47.5K	0.3%	65
2023 Q1	$296K	Buy	46,429 +1,747	+4%	+$18.2K	0.35%	52
2022 Q4	$676K	Buy	44,682 +8,968	+25%	+$66.8K	0.81%	43
2022 Q3	$230K	Buy	+35,714	New	+$439K	0.26%	68

Other funds holding EDSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CM Management's EDSA Position: Q1 2025 in Review

CM Management sold out of Edesa Biotech (EDSA) in Q1 2025, closing a stake of 110,000 shares — an estimated $185K sold.

CM Management first reported a position in EDSA in Q3 2022 and held it in 10 quarters. The position peaked at $676K in Q4 2022. 20 funds tracked by Wall St. Rank hold EDSA as of Q1 2025.

CM Management reported no remaining Edesa Biotech position as of Q1 2025 after selling out during the quarter.
CM Management sold 110,000 Edesa Biotech shares in Q1 2025, an estimated $185K.
CM Management first reported a position in Edesa Biotech in Q3 2022 and held it in 10 quarters.
CM Management's Edesa Biotech position peaked at $676K in Q4 2022.
20 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2025.

Based on CM Management's 13F filing for Q1 2025, filed 9 May 2025.